248 related articles for article (PubMed ID: 17938252)
21. Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Bieker R; Kessler T; Berdel WE; Mesters RM
Oncol Rep; 2003; 10(6):1915-7. PubMed ID: 14534718
[TBL] [Abstract][Full Text] [Related]
22. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
[TBL] [Abstract][Full Text] [Related]
23. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
[TBL] [Abstract][Full Text] [Related]
24. Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma.
Galán L; Sánchez AC; Cantos B; Provencio M
Clin Transl Oncol; 2010 May; 12(5):384-6. PubMed ID: 20466624
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
[TBL] [Abstract][Full Text] [Related]
26. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
27. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Hartmann S; Eichenauer DA; Plütschow A; Mottok A; Bob R; Koch K; Bernd HW; Cogliatti S; Hummel M; Feller AC; Ott G; Möller P; Rosenwald A; Stein H; Hansmann ML; Engert A; Klapper W
Blood; 2013 Dec; 122(26):4246-52; quiz 4292. PubMed ID: 24100447
[TBL] [Abstract][Full Text] [Related]
28. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
29. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
[TBL] [Abstract][Full Text] [Related]
30. Re-treatment of relapsed indolent B-cell lymphoma with rituximab.
Igarashi T; Ohtsu T; Fujii H; Sasaki Y; Morishima Y; Ogura M; Kagami Y; Kinoshita T; Kasai M; Kiyama Y; Kobayashi Y; Tobinai K;
Int J Hematol; 2001 Feb; 73(2):213-21. PubMed ID: 11372734
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of 2 patients treated with
Golstein SC; Muylle K; Vercruyssen M; Spilleboudt C; de Wind A; Bron D
Eur J Haematol; 2018 Sep; 101(3):415-417. PubMed ID: 29719928
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
[TBL] [Abstract][Full Text] [Related]
33. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Mocikova H; Pytlik R; Stepankova P; Michalka J; Markova J; Koren J; Buresova L; Raida L; Kral Z
Acta Haematol; 2015; 134(3):187-92. PubMed ID: 26021284
[TBL] [Abstract][Full Text] [Related]
34. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma.
Boudová L; Torlakovic E; Delabie J; Reimer P; Pfistner B; Wiedenmann S; Diehl V; Müller-Hermelink HK; Rüdiger T
Blood; 2003 Nov; 102(10):3753-8. PubMed ID: 12881319
[TBL] [Abstract][Full Text] [Related]
35. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
Nogová L; Rudiger T; Engert A
Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; Sasse S; Baues C; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2020 Mar; 38(7):698-705. PubMed ID: 31626571
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
Dang NH; Fayad L; McLaughlin P; Romaguara JE; Hagemeister F; Goy A; Neelapu S; Samaniego F; Walker PL; Wang M; Rodriguez MA; Tong AT; Pro B
Br J Haematol; 2007 Aug; 138(4):502-5. PubMed ID: 17608763
[TBL] [Abstract][Full Text] [Related]
38. Rituximab in lymphocyte predominance Hodgkin's disease: a case series.
Ibom VK; Prosnitz RG; Gong JZ; Moore JO; DeCastro CM; Prosnitz LR; Rizzieri DA; Gockerman JP
Clin Lymphoma; 2003 Sep; 4(2):115-8. PubMed ID: 14556684
[TBL] [Abstract][Full Text] [Related]
39. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
